Montrusco Bolton Investments Inc. Has $382.94 Million Position in Danaher Co. (NYSE:DHR)

Montrusco Bolton Investments Inc. grew its position in shares of Danaher Co. (NYSE:DHR) by 0.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,715,826 shares of the conglomerate’s stock after buying an additional 9,942 shares during the period. Danaher makes up 4.6% of Montrusco Bolton Investments Inc.’s holdings, making the stock its 6th biggest position. Montrusco Bolton Investments Inc. owned 0.24% of Danaher worth $382,936,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Decker Retirement Planning Inc. bought a new position in Danaher in the 4th quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher during the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. acquired a new position in Danaher during the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher in the 3rd quarter worth about $50,000. Finally, Darwin Wealth Management LLC bought a new position in Danaher during the 3rd quarter valued at $55,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Scotiabank initiated coverage on shares of Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a report on Thursday, October 31st. UBS Group reduced their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Finally, Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Six investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $285.81.

Danaher Stock Down 1.1 %

DHR opened at $247.77 on Wednesday. The company has a market cap of $178.96 billion, a PE ratio of 47.29, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a 50-day moving average price of $236.09 and a 200 day moving average price of $253.66. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same quarter in the previous year, the company earned $2.09 earnings per share. Sell-side analysts expect that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.